| Products | Technical Support | Search | Sitemap | Contact | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| INSTITUTE OF ISOTOPES CO., LTD. | Thyroxine (T4) RIA kit (RK-11M1) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| COMPANY About Us Contact BUSINESS UNITS Radiopharmaceutical Immunoassay Molecular Biology Synthesis Radiation Technique PRODUCTS Complete List New Products Technical Support QUOTATION REQUEST SEARCH || Sitemap *** Magyar *** |
DescriptionThe T4 [125I] RIA system provides a quantitative in vitro determination of thyroxine (T4) in human serum in the range 0-320 nmol/l (0-24.9 µg/dl). IntroductionT4 (3,5,3’,5’-tetraiodothyronine, MW 777) is the primary active hormone synthesized within the follicular cells of thyroid gland. In plasma, ~70% of T4 is bound to thyroxine-binding globulin (TBG), 15-25% to transthyretin, 5-15% to albumin and a small percentage is bound to erythrocytes. Less than 0.1% of total T4 circulates in a free or unbound form. T4 bounds to specific cell receptors and has diverse cellular and somatic effects. T4 is catabolized by several processes, including deiodination, transamination followed by oxidative decarboxylation and conjugation. In most patiens the total T4 level is a good indicator of thyroid status, but T4 levels may be altered in conditions affecting the capacity of the thyroid hormone binding proteins, e. g. pregnancy. Principle of methodThis assay is based on the competition between unlabelled T4 and a fixed quantity of 125I-labelled T4 for a limited number of binding sites on T4 specific antibody. Allowing to react a fixed amount of tracer and antibody with different amounts of unlabelled ligand the amount of tracer bound by the antibody will be inversely proportional to the concentration of unlabelled ligand. Upon addition of magnetizable immunosorbent the antigen-antibody complex is bound on solid particles which are then separated by either magnetic sedimentation or centrifugation. Counting the radioactivity of solid phase enables a standard curve to be constructed and samples to be quantitated. Contents of the kit
Materials, tools and equipment requiredRound
bottom polystyrene or polypropylene assay tubes, about 12 x 75 mm Recommended tools and equipment Orbital
shaker Specimen collection and storageSerum samples can be prepared according to common procedures used routinely in clinical laboratory practice. Samples can be stored at 2-8 °C if the assay is carried out within 24 hours, otherwise aliquots should be prepared and stored deep frozen (-20 °C). Frozen samples should be thawed and thoroughly mixed before assaying. Repeated freezing and thawing should be avoided. Do not use lipemic, hemolyzed or turbid specimens. Preparation of reagents, storageStore the reagents between 2-8 °C after opening. At this temperature each reagent is stable until expiry date. The actual expiry date is given on the package label and in the quality certificate. Add 500 µl distilled water to the lyophilised control serum. Mix gently with shaking or vortexing (foaming should be avoided). Ensure that complete dissolution is achieved, and allow the solution to equilibrate at room temperature for at least 20 minutes. Store at 2-8 °C until expiry date. CAUTION! Equilibrate all reagents and serum samples to room temperature. Mix all reagents and samples thoroughly before use. Avoid excessive foaming. Assay procedure(For a quick guide refer to Table 1)
Table 1. Assay Protocol, Pipetting Guide (all volumes in microliters)
Calculation of resultsThe
calculation is illustrated using representative data. The assay data collected should be
similar to those shown in Table 2.
B0/T% is an optional quality control parameter unnecessary for determination of sample concentrations. Calculate the normalized percent binding for each standard, control and sample respectively by using the following equation:
For simplicity, these values are uncorrected for non-specific binding (NSB). This is enabled by low NSB being less than 3% of total count. Using semi-logarithmic graph paper plot B / B0 % for each standard versus the corresponding concentration of thyroxine. Figure 1 shows a typical standard curve. Determine the T4 concentration of the unknown samples by interpolation from the standard curve. Do not extrapolate values beyond the standard curve range. Out of fitting programs applied for computerized data processing logit-log, or spline fittings can be used. Table 2. Typical Assay Data
Characterization of the assayAssay parameters
Specificity Cross reactivity values are shown below.
Sensitivity Better than 0.094 nmol/l, corresponding to the 0-2xSD value. Precision 6 control samples were assayed in 10 replicates to determine intraassay precision. Values obtained are shown below.
Reproducibility To determine interassay precision 6 samples were measured in duplicates in 6-9 independent assays. Values obtained are shown below.
Recovery Recovery was defined as the measured increase expressed as percent of expected increase upon spiking serum samples with known amount of T4. The mean (± SD) recovery % for added T4 (5 samples, 100 nM added T4) was 95 ± 2.4. Expected
reference values In a population (n = 115) of adult female blood donors (ages: mean 36.8 ± 11.5, range (18-61), the mean (± SD) serum concentration of thyroxine (T4) was 122.4 ± 31.2 range (70.6-204.8). As a guide, 78–190 nmol/l was obtained from normal patients. In a population (n = 119) of adult male blood donors (ages: mean 39.7 ± 11.9, range (19–64), the mean (± SD) serum concentration of thyroxine (T4) was 108.2 ± 17.8 range (63.8–148.2). As a guide, 70 -140 nmol/l was obtained from normal patients. For female and male (n = 234) the mean (± SD) serum concentration of thyroxine (T4) was 115.2 ± 26.2 range (63.8–204.8). As a guide, 78–185 nmol/l was obtained from normal patients. The results obtained should only be interpreted in the context of the overall clinical picture. None of the in vitro diagnostic kits can be used as the one and only proof of any disease or disorder. Conversion of SI units can be performed according to the following formula: 1
nmol/l = 0.078 µg/dl Additional informationComponents from various lots or from kits of different manufacturers should not be mixed or interchanged. PrecautionRadioactivity This product contains radioactive material. It is the responsibility of the user to ensure that local regulations or code of practice related to the handling of radioactive materials are satisfied. Biohazard Human blood products used in the kit have been obtained from healthy human donors. They were tested individually by using approved methods (EIA, enzyme immunoassay), and were found to be negative, for the presence of both Human Immunodeficiency Virus antibody (Anti-HIV-1) and Hepatitis B surface Antigen (HBsAg). Care should always be taken when handling human specimens to be tested with diagnostic kits. Even if the subject has been tested, no method can offer complete assurance that Hepatitis B Virus, Human Immunodeficiency Virus (HIV-1), or other infectious agents are absent. Human blood samples should therefore be handled as potentially infectious materials. Chemical hazard Components contain sodium azide as an antimicrobial agent. Dispose of waste by flushing with copious amount of water to avoid build-up of explosive metallic azides in copper and lead plumbing. The total azide present in each pack is 69.5 mg.
Products || Technical Support || Search || Sitemap || Contact || Quotation Request |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||